323 related articles for article (PubMed ID: 23441652)
1. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.
Holmes NE; Turnidge JD; Munckhof WJ; Robinson JO; Korman TM; O'Sullivan MV; Anderson TL; Roberts SA; Warren SJ; Gao W; Johnson PD; Howden BP
Clin Microbiol Infect; 2013 Dec; 19(12):1163-8. PubMed ID: 23441652
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.
Holmes NE; Turnidge JD; Munckhof WJ; Robinson JO; Korman TM; O'Sullivan MV; Anderson TL; Roberts SA; Gao W; Christiansen KJ; Coombs GW; Johnson PD; Howden BP
J Infect Dis; 2011 Aug; 204(3):340-7. PubMed ID: 21742831
[TBL] [Abstract][Full Text] [Related]
3. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
[TBL] [Abstract][Full Text] [Related]
4. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
5. No effect of vancomycin MIC ≥ 1.5 mg/L on treatment outcome in methicillin-susceptible Staphylococcus aureus bacteraemia.
Bouiller K; Laborde C; Aho SL; Hocquet D; Pechinot A; Le Moing V; Bertrand X; Piroth L; Chirouze C
Int J Antimicrob Agents; 2018 May; 51(5):721-726. PubMed ID: 29305961
[TBL] [Abstract][Full Text] [Related]
6. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
7. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
[TBL] [Abstract][Full Text] [Related]
8. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
[TBL] [Abstract][Full Text] [Related]
9. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
Shoji H; Maeda M; Shirakura T; Takuma T; Ugajin K; Fukuchi K; Ishino K; Niki Y
Int J Antimicrob Agents; 2015 Nov; 46(5):532-7. PubMed ID: 26364848
[TBL] [Abstract][Full Text] [Related]
10. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.
Kan LP; Lin JC; Chiu SK; Yeh YC; Lin TY; Yang YS; Wang YC; Wang NC; Yeh KM; Chang FY
J Microbiol Immunol Infect; 2014 Feb; 47(1):15-22. PubMed ID: 23040238
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.
Falcón R; Mateo E; Oltra R; Giménez E; Albert E; Torres I; Navarro D
Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):903-912. PubMed ID: 30729396
[TBL] [Abstract][Full Text] [Related]
13. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chang SC; Hsueh PR
J Antimicrob Chemother; 2014 Jan; 69(1):211-8. PubMed ID: 23997017
[TBL] [Abstract][Full Text] [Related]
14. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
[TBL] [Abstract][Full Text] [Related]
15. High vancomycin minimum inhibitory concentration is associated with poor outcome in patients with methicillin-susceptible Staphylococcus aureus bacteremia regardless of treatment.
Castón JJ; González-Gasca F; Porras L; Illescas S; Romero MD; Gijón J
Scand J Infect Dis; 2014 Nov; 46(11):783-6. PubMed ID: 25134647
[TBL] [Abstract][Full Text] [Related]
16. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
Chen SY; Hsueh PR; Chiang WC; Huang EP; Lin CF; Chang CH; Chen SC; Chen WJ; Chang SC; Lai MS; Chie WC
J Infect; 2014 Sep; 69(3):259-65. PubMed ID: 24797078
[TBL] [Abstract][Full Text] [Related]
17. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .
Lodise TP; Drusano GL; Lazariu V; El-Fawal N; Evans A; Graffunder E; Stellrecht K; Mendes RE; Jones RN; Cosler L; McNutt LA
J Antimicrob Chemother; 2014 Sep; 69(9):2547-55. PubMed ID: 24840624
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context.
Hope R; Blackburn RM; Verlander NQ; Johnson AP; Kearns A; Hill R; Hopkins S; Sheridan E; Livermore DM; ;
J Antimicrob Chemother; 2013 Nov; 68(11):2641-7. PubMed ID: 23794604
[TBL] [Abstract][Full Text] [Related]
19. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence.
Forstner C; Dungl C; Tobudic S; Mitteregger D; Lagler H; Burgmann H
Clin Microbiol Infect; 2013 Jul; 19(7):E291-7. PubMed ID: 23490021
[TBL] [Abstract][Full Text] [Related]
20. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study.
Goldberg E; Paul M; Talker O; Samra Z; Raskin M; Hazzan R; Leibovici L; Bishara J
J Antimicrob Chemother; 2010 Aug; 65(8):1779-83. PubMed ID: 20507860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
